DRUGS FOR NEGLECTED DISEASESINITIATIVE NORTH AMERICA INC
EIN 20-8774179 NEW YORK, NY
- Revenue 2024
- $6,221,917
- Expenses 2024
- $6,349,740
Program services were 80.6% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
As filed
- Subsection
- 03
- NTEE code
- E05
- Classification
- 1000
- Street
- 40 RECTOR STREET 16TH FLOOR
These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).
Mission and programs · 2024
Mission
THE MISSION OF DNDI NORTH AMERICA IS TO CONTRIBUTE TO THE ACHIEVEMENT OF DNDI'S GLOBAL OBJECTIVES, IN PARTICULAR TO STRENGHTEN AND EXPAND DNDI'S SCIENTIFIC, POLICY ADVOCACY, FUNDRAISING, AND COMMUNICATIONS EFFORTS IN NORTH AMERICA BY (A) PROVIDING FOCUSED SUPPORT FOR SPECIFIC R&D PROJECTS AND BUSINESS/PARTNER DEVELOPMENT ACTIVITIES IN NORTH AMERICA;(B) ACHIEVING CONCRETE POLICY CHANGES IN NORTH AMERICA TO CREATE A MORE FAVORABLE ENVIRONMENT FOR NEEDS-DRIVEN R&D FOR NEGLECTED DISEASES;(C) MOBILIZING PUBLIC AND PRIVATE FUNDS IN NORTH AMERICA TO SUPPORT DNDI'S MISSION;(D) INCREASING DNDI'S PROFILE AND VISIBILITY IN NORTH AMERICA, THEREBY DRAWING GREATER PUBLIC ATTENTION TO THE NEED FOR NEGLECTED DISEASE R&D.
Activities or mission (Part I)
THE DRUGS FOR NEGLECTED DISEASES INITIATIVE (DNDI), NORTH AMERICA SUPPORTS DNDI'S GLOBAL VISION AND MISSION TO DEVELOP NEW DRUGS, OR NEW FORMULATIONS OF EXISTING DRUGS FOR PATIENTS SUFFERING FROM THE MOST NEGLECTED DISEASES. ACTING IN THE PUBLIC INTEREST, DNDI BRIDGES EXISTING R&D GAPS IN ESSENTIAL DRUGS FOR THESE DISEASES BY INITIATING AND COORDINATING DRUG R&D PROJECTS IN COLLABORATION WITH THE INTERNATIONAL RESEARCH COMMUNITY, THE PUBLIC SECTOR, THE PHARMACEUTICAL INDUSTRY, AND OTHER PARTNERS.
-
GRANTS TO RESEARCH AND DEVELOPMENT FOR NEGLECTED DISEASES: DNDI NORTH AMERICA RAISES FUNDS TO SUPPORT DNDI'S RESEARCH AND DEVELOPMENT (R&D) ACTIVITIES IN ORDER TO CONTRIBUTE TO THE ACHIEVEMENT OF DNDI'S GOAL OF DELIVERING 25 NEW TREATMENTS FOR NEGLECTED PATIENTS BY 2028 AND ESTABLISHING A ROBUST PIPELINE OF NEW POTENTIAL DRUG CANDIDATES. DNDI NOW HAS OVER 30 PROJECTS IN ITS PIPELINE, INCLUDING OVER 20 POTENTIAL NEW CHEMICAL ENTITIES (NCES), AND HAS DELIVERED 12 TREATMENTS OFR SIX DEADLY DISEASES THAT ARE ALREADY IN THE HANDS OF MILLIONS OF PATIENTS.
Expenses $5,117,384 · Grants $3,670,704
-
RAISING PUBLIC AWARENESS AND ADVOCATING FOR NEGLECTED DISEASE R&D:AS PART OF ITS MISSION, DNDI ADVOCATES FOR ENHANCED POLITICAL LEADERSHIP, INCREASED RESOURCES, AND AN ENABLING POLICY ENVIRONMENT TO STIMULATE R&D FOR NEGLECTED DISEASES. DNDI NORTH AMERICA ACTIVELY ADVOCATES FOR SOUND POLICIES, PARTICULARLY IN THE UNITED STATES, THAT WILL ENABLE GREATER NEEDS-DRIVEN R&D, INCLUDING APPROPRIATE INCENTIVES AND FINANCING MECHANISMS, INNOVATIVE REGULATORY PATHWAYS THAT EXPEDITE ACCESS, AND OPEN INNOVATION APPROACHES TO INTELLECTUAL PROPERTY MANAGEMENT THAT ENSURE THE WIDEST POSSIBLE SHARING OF RESEARCH KNOWLEDGE AND DATA.
As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.
Officers and directors · 2024
As listed in Part VII of the 2024 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.
-
LUIS PIZARRO
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 2
-
MEENA AHAMED
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 2
-
AFRICA STEWART
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 2
-
BENNETT SHAPIRO
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 2
-
KRISTINA TORGESON
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 2
-
DARIN PORTNOY
CHAIR OF THE BOARD
- Total calculated
- $0
- Hours/week
- 3
-
SHING CHANG
SECRETARY
- Total calculated
- $0
- Hours/week
- 2
-
JOHN LAWRENCE
TREASURER
- Total calculated
- $0
- Hours/week
- 2
-
DELALI ATTIPOE
EXECUTIVE DIRECTOR
- Total calculated
- $310,984
- From this org
- $239,914
- From related orgs
- $0
- Other
- $71,070
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $239,914
- Bonus
- $0
- Other
- $0
- Deferred
- $21,450
- Nontaxable benefits
- $49,620
- Filer's total
- $310,984
-
RACHEL COHEN
SENIOR ADVISOR, GLOBAL POL
- Total calculated
- $281,847
- From this org
- $213,183
- From related orgs
- $0
- Other
- $68,664
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $213,183
- Bonus
- $0
- Other
- $0
- Deferred
- $19,044
- Nontaxable benefits
- $49,620
- Filer's total
- $281,847
-
ILAN MOSS
HEAD OF MEDIA AND CONTENT
- Total calculated
- $170,416
- From this org
- $156,476
- From related orgs
- $0
- Other
- $13,940
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $156,476
- Bonus
- $0
- Other
- $0
- Deferred
- $13,940
- Nontaxable benefits
- $0
- Filer's total
- $170,416
-
VISHAL GOYAL
SENIOR CLINICAL PROJECT AN
- Total calculated
- $177,424
- From this org
- $146,409
- From related orgs
- $0
- Other
- $31,015
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $146,409
- Bonus
- $0
- Other
- $0
- Deferred
- $8,201
- Nontaxable benefits
- $22,814
- Filer's total
- $177,424
-
SHIRLEY LEUNG
SENIOR HR BUSINESS PARTNER
- Total calculated
- $150,994
- From this org
- $106,712
- From related orgs
- $0
- Other
- $44,282
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $106,712
- Bonus
- $0
- Other
- $0
- Deferred
- $9,461
- Nontaxable benefits
- $34,821
- Filer's total
- $150,994
-
RON SYKES
SENIOR INDIVIDUAL GIVING MANAGER
- Total calculated
- $151,647
- From this org
- $123,284
- From related orgs
- $0
- Other
- $28,363
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $123,284
- Bonus
- $0
- Other
- $0
- Deferred
- $10,953
- Nontaxable benefits
- $17,410
- Filer's total
- $151,647
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.
Filings
-
2024
- Revenue
- $6,221,917
- Expenses
- $6,349,740
- Contributions
- $6,193,831
- Grants paid
- $3,670,704
-
2023
- Revenue
- $4,350,936
- Expenses
- $4,172,304
- Contributions
- $4,335,949
- Grants paid
- $1,714,645
-
2022
- Revenue
- $3,931,942
- Expenses
- $3,853,071
- Contributions
- $3,908,555
- Grants paid
- $1,777,205
The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.
Other returns filed
-
2021 · 990
- Revenue
- $4,153,290
- Expenses
- $3,993,581
- Assets (EOY)
- $1,372,645
-
2020 · 990
- Revenue
- $3,738,262
- Expenses
- $3,585,571
- Assets (EOY)
- $1,506,481
-
2019 · 990
- Revenue
- $4,627,274
- Expenses
- $4,593,537
- Assets (EOY)
- $1,352,194
-
2018 · 990
- Revenue
- $5,843,041
- Expenses
- $6,026,040
- Assets (EOY)
- $2,330,609
-
2017 · 990
- Revenue
- $4,208,499
- Expenses
- $4,091,229
- Assets (EOY)
- $1,550,320
-
2016 · 990
- Revenue
- $3,218,982
- Expenses
- $2,986,726
- Assets (EOY)
- $795,298
-
2015 · 990
- Revenue
- $2,866,749
- Expenses
- $2,644,518
- Assets (EOY)
- $710,595
-
2014 · 990
- Revenue
- $1,989,652
- Expenses
- $1,922,714
- Assets (EOY)
- $216,111
-
2013 · 990
- Revenue
- $2,473,958
- Expenses
- $2,481,901
- Assets (EOY)
- $163,631
-
2012 · 990
- Revenue
- not reported
- Expenses
- $2,444,999
- Assets (EOY)
- $122,134
Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all. Showing the 10 most recent; the API carries the rest.
Grants made
No itemized grants to organizations. Schedule I is filed only by organizations that granted more than $5,000 to a recipient, so most filers have none.
Grants received
-
MEDECINS SANS FRONTIERES USA INC
$1,260,514
2023 MEDICAL ASSISTANCE
-
MEDECINS SANS FRONTIERES USA INC
$1,208,775
2022 MEDICAL ASSISTANCE
-
2023 FOR RECIPIENT'S EXEMPT PURPOSE
-
$100,300
2022 HEALTH
-
2022 FOR RECIPIENT'S EXEMPT PURPOSE
-
$22,572
2022 IN FURTHERANCE OF GRANTEE'S TAX-EXEMPT PURPOSE
-
$22,000
2023 HEALTH
-
DONOR ADVISED CHARITABLE GIVING
$17,500
2022 HEALTH
-
2023 For grant recipient's exempt purposes
-
THE AYCO CHARITABLE FOUNDATION
$15,000
2022 MEDICAL / PUBLIC SERVICES
The 10 largest by cash amount. The API serves every itemized grant.
Other IRS files
Auto-Revocation List
Not listed. The IRS publishes this list for organizations whose exemption was automatically revoked for failing to file for three consecutive years.
Publication 78
Listed as of 13 October 2026, under deductibility PC.
These are two separate IRS files on two separate schedules, shown as published and not reconciled with each other. Neither is a statement about whether a contribution is deductible today: 19,245 organizations appear in Publication 78 while the IRS's own revocation file lists them as currently revoked, more than half of those revoked before 2019. Absence from Publication 78 is evidence of nothing, and presence is not evidence either. Verify current status with the IRS before relying on it.
What this page reflects
The registration facts above come from the IRS Business Master File published 13 October 2026 and read 29 October 2026, for every organization at once. Returns through tax year 2024, the newest we have parsed for this organization.